Form 8-K - Current report:
SEC Accession No. 0001193125-22-089949
Filing Date
2022-03-30
Accepted
2022-03-30 16:51:18
Documents
15
Period of Report
2022-03-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d339551d8k.htm   iXBRL 8-K 28765
2 EX-99.1 d339551dex991.htm EX-99.1 90391
7 GRAPHIC g339551g0329214105585.jpg GRAPHIC 3590
  Complete submission text file 0001193125-22-089949.txt   301423

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA crxt-20220330.xsd EX-101.SCH 4482
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE crxt-20220330_def.xml EX-101.DEF 14244
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE crxt-20220330_lab.xml EX-101.LAB 23885
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE crxt-20220330_pre.xml EX-101.PRE 15271
9 EXTRACTED XBRL INSTANCE DOCUMENT d339551d8k_htm.xml XML 5823
Mailing Address 555 SKOKIE BOULEVARD, SUITE 340 NORTHBROOK IL 60062
Business Address 555 SKOKIE BOULEVARD, SUITE 340 NORTHBROOK IL 60062 (847) 562-4300
Clarus Therapeutics Holdings, Inc. (Filer) CIK: 0001817944 (see all company filings)

EIN.: 851231852 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39802 | Film No.: 22787234
SIC: 2836 Biological Products, (No Diagnostic Substances)